<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01059435</url>
  </required_header>
  <id_info>
    <org_study_id>20060220</org_study_id>
    <nct_id>NCT01059435</nct_id>
  </id_info>
  <brief_title>A First-in-human Study Evaluating AMG 785 in Healthy Men and Postmenopausal Women</brief_title>
  <official_title>A Randomized, Double-blind, Placebo-controlled, Ascending Single-dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 785 in Healthy Men and Postmenopausal Women</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Amgen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Amgen</source>
  <brief_summary>
    <textblock>
      The primary objective of this study is to assess the safety and tolerability of AMG 785
      following a single dose subcutaneous (SC) or intravenous (IV) administration in healthy men
      and postmenopausal women.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2006</start_date>
  <completion_date type="Actual">August 2008</completion_date>
  <primary_completion_date type="Actual">July 2007</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The number of subjects reporting treatment-emergent adverse events.</measure>
    <time_frame>Maximum of 85 days.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>The number of subjects experiencing clinically significant changes in safety laboratory tests, physical examinations, vital signs, or electrocardiograms (ECGs).</measure>
    <time_frame>Maximum of 85 days.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>The number of subjects who develop antibodies to AMG 785.</measure>
    <time_frame>Maximum of 85 days.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic and pharmacodynamic parameters [serum procollagen type 1 N-terminal propeptide (P1NP), BSAP, osteocalcin, sCTX, intact parathyroid hormone (iPTH), serum and ionized calcium, and sclerostin levels].</measure>
    <time_frame>Maximum of 85 days.</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">74</enrollment>
  <condition>Osteopenia</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Two female subjects in each of cohorts 1, 2, 3a, 4, 5, and 6a will receive placebo; two male subjects in each of cohorts 3b and 6b; and 1 female subject in each of cohorts 3c and 6c.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Two female subjects in each of cohorts 1, 2, 3a, 4, 5, and 6a will receive AMG 785; two male subjects in each of cohorts 3b and 6b; and 1 female subject in each of cohorts 3c and 6c.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AMG 785</intervention_name>
    <description>Subjects will be randomized to receive 1 of 6 doses of AMG 785 or equivalent volume of placebo administered as a single dose. Postmenopausal women will receive AMG 785 or placebo as a weight-based dose of 0.1 mg/kg, 0.3, 1, 3, 5, or 10 mg/kg subcutaneously (SC, under the skin), or 1 mg/kg or 5 mg/kg intravenously (IV, in the vein), while men will receive doses of 1 mg/kg or 5 mg/kg SC or IV.</description>
    <arm_group_label>A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Subjects will be randomized to receive 1 of 6 doses of AMG 785 or equivalent volume of placebo administered as a single dose. Postmenopausal women will receive AMG 785 or placebo as a weight-based dose of 0.1 mg/kg, 0.3, 1, 3, 5, or 10 mg/kg subcutaneously (SC, under the skin), or 1 mg/kg or 5 mg/kg intravenously (IV, in the vein), while men will receive doses of 1 mg/kg or 5 mg/kg SC or IV.</description>
    <arm_group_label>B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy males or female between 45 to 59 years of age, inclusive

          -  Postmenopausal females defined as 12 continuous months of spontaneous amenorrhea
             confirmed by a serum follicle-stimulating hormone (FSH) result &gt; 40mIU/mL, or 6 weeks
             postsurgical bilateral oophorectomy (with or without hysterectomy)

          -  Males must agree to use a condom during sexual intercourse with female partners who
             are of reproductive potential and to have their female partners use an additional
             effective means of contraception or to abstain from sexual intercourse for the
             duration of the study

          -  Has no history or evidence of a clinically significant disorder, condition or disease
             that would pose a risk to subject safety or interfere with the study evaluation,
             procedures or completion

        Exclusion Criteria:

          -  Diagnosed with any condition that will affect bone metabolism

          -  Administration of the following medications within 6 months before study drug
             administration:

          -  Hormone replacement therapy [Infrequent use of estrogen vaginal creams (&lt; 3 times per
             week) is allowed.]

          -  Calcitonin

          -  Parathyroid hormone (or any derivative)

          -  Supplemental Vitamin D &gt; 1,000 IU/day

          -  Glucocorticosteroids (inhaled or topical corticosteroids administered more than 2
             weeks before the enrollment date are allowed)

          -  Anabolic steroids

          -  Calcitriol, and available analogues

          -  Administration of the following medications within 12 months before study drug
             administration:

          -  Bisphosphonates

          -  Fluoride for osteoporosis

          -  Administration of herbal medications within 2 weeks or 5 half-lives (whichever is
             longer) before study drug administration

          -  Greatly differing levels of physical activity or constant levels of intense physical
             exercise during the 6 months before study drug administration

          -  Routine alcohol intake of &gt; 2 drinks per day, on average, within 6 months of study
             drug administration

          -  Known sensitivity to mammalian-derived drug preparations

          -  Known to be hepatitis B surface antigen, hepatitis C virus, or human immunodeficiency
             virus (HIV) positive, or a known diagnosis of acquired immunodeficiency syndrome
             (AIDS)

          -  Any organic or psychiatric disorder which may pose a risk to subject safety and may
             prevent the subject from completing the study or interfere with the interpretation of
             the study results

          -  Unavailable for follow-up assessment or any concerns for subject's compliance with the
             protocol procedures

          -  Any other condition that might reduce the chance of obtaining data required by the
             protocol or that might compromise the ability to give truly informed consent

          -  Has a history of drug or alcohol abuse with the last 12 months and/or a positive urine
             test result at screening or admission

          -  Has any clinically significant abnormality during the screening physical examination,
             electrocardiogram (ECG), or laboratory evaluation

          -  Has participated in another clinical study within 4 weeks of screening or within 5
             times the half-life of the investigational agent in the other clinical study, if known

          -  Weight ≥ 98 kilograms (216 pounds) and/or height ≥ 78 inches

          -  Has donated or lost 400 milliliters or more of blood or plasma within 8 weeks of study
             drug administration
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>59 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>MD</last_name>
    <role>Study Director</role>
    <affiliation>Amgen</affiliation>
  </overall_official>
  <link>
    <url>http://www.amgentrials.com</url>
    <description>AmgenTrials clinical trials website</description>
  </link>
  <results_reference>
    <citation>Padhi D, Jang G, Stouch B, Fang L, Posvar E. Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody. J Bone Miner Res. 2011 Jan;26(1):19-26. doi: 10.1002/jbmr.173.</citation>
    <PMID>20593411</PMID>
  </results_reference>
  <verification_date>May 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 28, 2010</study_first_submitted>
  <study_first_submitted_qc>January 29, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 1, 2010</study_first_posted>
  <last_update_submitted>May 1, 2013</last_update_submitted>
  <last_update_submitted_qc>May 1, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 3, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Amgen</keyword>
  <keyword>First in Human</keyword>
  <keyword>Postmenopausal</keyword>
  <keyword>Phase 1</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bone Diseases, Metabolic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

